[1]
|
Siegel, R., Naishadham, D. and Jemal, A. (2013) Cancer Statistics. CA: A Cancer Journal for Clinicians, 63, 11-30. https://doi.org/10.3322/caac.21166
|
[2]
|
Ries, L.A.G., Melbert, D., Krapcho, M., et al. (2008) SEER Cancer Statistics Review, 1975-2005. National Cancer Institute, Bethesda, MD.
|
[3]
|
Lu-Yao, G.L., Albertsen, P.C., Moore, D.F., et al. (2009) Outcomes of Localized Prostate Cancer Following Conservative Management. JAMA, 302, 1202-1209. https://doi.org/10.1001/jama.2009.1348
|
[4]
|
Cooperberg, M.R., Broering, J.M., Kantoff, P.W. and Carroll, P.R. (2007) Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment. Journal of Urology, 178, S14-S19. https://doi.org/10.1016/j.juro.2007.03.135
|
[5]
|
Loeb, S., Berglund, A. and Stattin, P. (2013) Population-Based Study of Utilization and Determinants of Active Surveillance and Watchful Waiting for Low- and Intermediate-Risk Prostate Cancer. Journal of Urology, 190, 1742-1749. https://doi.org/10.1016/j.juro.2013.05.054
|
[6]
|
D’Amico, A.V. (2002) Combined-Modality Staging in Predicting Prostate-Specific Antigen Outcome after Definitive Local Therapy for Men with Clinically Localized Prostate Cancer. In: Prostate Cancer: Principles & Practice, Lippincott Williams & Wilkins, Philadelphia, PA, 254-268.
|
[7]
|
Cooperberg, M.R., Pasta, D.J., Elkin, E.P., Litwin, M.S., Latini, D.M., Du Chane, J. and Carroll, P.R. (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment Score: A Straightforward and Reliable Preoperative Predictor of Disease Recurrence after Radical Prostatectomy. Journal of Urology, 173, 1938-1942. https://doi.org/10.1097/01.ju.0000158155.33890.e7
|
[8]
|
Kattan, M.W., Eastham, J.A., Stapleton, A.M., Wheeler, T.M. and Scardino, P.T. (1998) A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer. Journal of the National Cancer Institute, 90, 766-771. https://doi.org/10.1093/jnci/90.10.766
|
[9]
|
Nakanishi, H., Wang, X., Ochiai, A., et al. (2007) A Nomogram for Predicting Low-Volume/Low-Grade Prostate Cancer: A Tool in Selecting Patients for Active Surveillance. Cancer, 110, 2441-2447. https://doi.org/10.1002/cncr.23055
|
[10]
|
Bangma, C.H., Roobol, M.J. and Steyerberg, E.W. (2009) Predictive Models in Diagnosing Indolent Cancer. Cancer, 115, 3100-3106. https://doi.org/10.1002/cncr.24347
|
[11]
|
Iremashvili, V., Burdick-Will, J. and Soloway, M.S. (2013) Improving Risk Stratification in Patients with Prostate Cancer Managed by Active Surveillance: A Nomogram Predicting the Risk of Biopsy Progression. BJU International, 112, 39-44. https://doi.org/10.1111/bju.12112
|
[12]
|
Conti, S.L., Dall’ ERA, M., Fradet, V., Cowan, J.E., Simko, J. and Carroll, P.R. (2009) Pathological Outcomes of Candidates for Actives Surveillance of Prostate Cancer. Journal of Urology, 181, 1628-1633. https://doi.org/10.1016/j.juro.2008.11.107
|
[13]
|
Latini, D.M., Hart, S.L., Knight, S.J., Cowan, J.E., Ross, P.L., Duchane, J. and Carroll, P.R. (2007) CaPSURE Investigators: The Relationship between Anxiety and Time to Treatment for Patients with Prostate Cancer on Surveillance. Journal of Urology, 178, 826-831. https://doi.org/10.1016/j.juro.2007.05.039
|
[14]
|
Cooperberg, M.R., Broering, J.M. and Caroll, P.R. (2010) Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 28, 1117-1123. https://doi.org/10.1200/JCO.2009.26.0133
|
[15]
|
Pardo, Y., Guedea, F., Aguilo, F., et al. (2010) Quality-of-Life Impact of Primary Treatments for Localized Prostate Cancer in Patients without Hormonal Treatment. Journal of Clinical Oncology, 28, 4687-4696. https://doi.org/10.1200/JCO.2009.25.3245
|
[16]
|
Sanda, M.G., Dunn, R.L., Michalski, J., et al. (2008) Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors. The New England Journal of Medicine, 358, 1250-1261. https://doi.org/10.1056/NEJMoa074311
|
[17]
|
Draisma, G., Etzioni, R., Tsodikov, A., Mariotto, A., Wever, E., Gulati, R., Feuer, E. and de Koning, H. (2009) Lead Time and over Diagnostic in Prostate Specific Antigen Screening: Importance of Methods and Context. Journal of the National Cancer Institute, 101, 374-383. https://doi.org/10.1093/jnci/djp001
|
[18]
|
Moyer, V.A., et al. (2012) Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, 157, 120-134. https://doi.org/10.7326/0003-4819-157-2-201207170-00459
|
[19]
|
Scosyrev, E., Wu, G., Mohile, S. and Messing, F.M. (2012) Prostate Specific Antigen Screening for Prostate Cancer and Risk of Overt Metastatic Disease at Presentation: Analysis of Trends over Time. Cancer, 118, 5768-5776. https://doi.org/10.1002/cncr.27503
|
[20]
|
Ganz, P.A., Barry, J.M., Burke, W., et al. (2012) National Institutes of Health State-of-the-Science Conference: Role of Active Surveillance in the Management of Men with Localized Prostate Cancer. Annals of Internal Medicine, 156, 591-595. https://doi.org/10.7326/0003-4819-156-8-201204170-00010
|
[21]
|
Dall’Era, M.A., Cooperberg, M.R., Chan, J.M., et al. (2008) Active Surveillance for Early-Stage Prostate Cancer: Review of the Current Literature. Cancer, 112, 1650-1659. https://doi.org/10.1002/cncr.23373
|
[22]
|
Warlick, C., Trock, B.J., Landis, P., et al. (2006) Delayed versus Immediate Surgical Intervention and Prostate Cancer Outcome. Journal of the National Cancer Institute, 98, 355-357. https://doi.org/10.1093/jnci/djj072
|
[23]
|
Cooperberg, M.R., Cowan, J.E., Hilton, J.F., et al. (2011) Outcomes of Active Surveillance for Men with Intermediate-Risk Prostate Cancer. Journal of Clinical Oncology, 29, 228-234. https://doi.org/10.1200/JCO.2010.31.4252
|
[24]
|
Van As, N.J., Norman, A.R., Thomas, K., et al. (2008) Predicting the Probability of Deferred Radical Treatment for Localized Prostate Cancer Managed by Active Surveillance. European Urology, 54, 1297-1305. https://doi.org/10.1016/j.eururo.2008.02.039
|
[25]
|
Catalona, W.J. (2012) Words of Wisdom. Re: Radical Prostatectomy versus Observation for Localized Prostate Cancer. European Urology, 62, 1195. https://doi.org/10.1016/j.eururo.2012.09.015
|
[26]
|
Cheng, J.Y. (2013) The Prostate Cancer Intervention versus Observation Trial (PIVOT) in Perspective. Journal of Clinical Medicine Research, 5, 266-268. https://doi.org/10.4021/jocmr1395w
|
[27]
|
Xia, J., Gulati, R., Au, M., Gore, J.L., Lin, D.W. and Etzioni, R. (2013) Effects of Screening on Radical Prostatectomy Efficacy: The Prostate Cancer Intervention versus Observation Trial. Journal of the National Cancer Institute, 105, 546-550. https://doi.org/10.1093/jnci/djt017
|
[28]
|
Albertsen, P.C., Hanley, J.A. and Fine, J. (2005) 20-Year Outcomes Following Conservative management of Clinically Localized Prostate Cancer. JAMA, 293, 2095-2101. https://doi.org/10.1001/jama.293.17.2095
|
[29]
|
Ross, A.E., Loeb, S., Landis, P., et al. (2010) Prostate-Specific Antigen Kinetics during Follow-Up Are an Unreliable Trigger for Intervention in a Prostate Cancer Surveillance Program. Journal of Clinical Oncology, 28, 2810-2816. https://doi.org/10.1200/JCO.2009.25.7311
|
[30]
|
Porten, S.P., Whitson, J.M., Cowan, J.E., et al. (2011) Changes in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance. Journal of Clinical Oncology, 29, 2795-2800. https://doi.org/10.1200/JCO.2010.33.0134
|
[31]
|
Reese, A.C., Pierorazio, P.M., Han, M. and Partin, A.W. (2012) Contemporary Evaluation of the National Comprehensive Cancer Network Prostate Cancer Risk Classification System. Urology, 80, 1075-1079. https://doi.org/10.1016/j.urology.2012.07.040
|
[32]
|
Mitchell, J.A., Cooperberg, M.R., Elkin, E.P., Lubeck, D.P., Mehta, S.S., Kane, C.J. and Carroll, P.R. (2005) Ability of 2 Pretreatment Risk Assessment Methods to Predict Prostate Cancer Recurrence after Radical Prostatectomy: Data from CaPSURE. Journal of Urology, 173, 1126-1131. https://doi.org/10.1097/01.ju.0000155535.25971.de
|
[33]
|
Porten, S.P., Cooperberg, M.R. and Carroll, P.R. (2010) The Independent Value of Tumour Volume in a Contemporary Cohort of Men Treated with Radical Prostatectomy for Clinically Localized Disease. BJU International, 105, 472-475. https://doi.org/10.1111/j.1464-410X.2009.08774.x
|
[34]
|
Solomon, K., Levrel, O., Anastasiadis, A.G., et al. (2003) Prognostic Significance of Tumor Volume after Radical Prostatectomy: Amultivariate Analysis of Pathological Prognostic Factors. European Urology, 43, 39-44. https://doi.org/10.1016/S0302-2838(02)00493-1
|
[35]
|
Kikuchi, E., Scardino, P.T., Wheeler, T.M., et al. (2004) Is Tumor Volume an Independent Prognostic Factor in Clinically Localized Prostate Cancer? Journal of Urology, 172, 508-511. https://doi.org/10.1097/01.ju.0000130481.04082.1a
|
[36]
|
Nelson, B.A., Shappell, S.B., Change, S.S., et al. (2006) Tumour Volume Is an Independent Predictor of Prostate-Specific Antigen Recurrence in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer. BJU International, 97, 1169-1172. https://doi.org/10.1111/j.1464-410X.2006.06148.x
|
[37]
|
Tosoian, J.J., Trock, B.J., Landis, P., et al. (2011) Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience. Journal of Clinical Oncology, 29, 2185-2190. https://doi.org/10.1200/JCO.2010.32.8112
|
[38]
|
Klotz, L., Zhang, L., Lam, A., et al. (2010) Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort with Localized Prostate Cancer. Journal of Clinical Oncology, 28, 126-131. https://doi.org/10.1200/JCO.2009.24.2180
|
[39]
|
Klotz, L. (2012) Active Surveillance: The Canadian Experience. Current Clinical Urology, 22, 222-230. https://doi.org/10.1007/978-1-61779-912-9_8
|
[40]
|
Abern, M.R., Aronson, W.J., Terris, M.K., Kane, C.J., Presti Jr., J.C., Amling, C.L. and Freedland, S.J. (2013) Delayed Radical Prostatectomy for Intermediate-Risk Prostate Cancer Is Associated with Biochemical Recurrence: Possible Implications for Active Surveillance from the SEARCH Database. The Prostate, 73, 409-417. https://doi.org/10.1002/pros.22582
|